Two diabetes drugs, two very different stories. One is a $900/month peptide injection with celebrity status. The other is a 70-year-old pill that costs $5. Here's what you should know before paying 180× more.
A GLP-1 receptor agonist peptide. Mimics the incretin hormone GLP-1 to increase insulin, suppress glucagon, slow stomach emptying, and reduce appetite. Once-weekly injection (Ozempic/Wegovy) or daily oral (Rybelsus).
A 70-year-old biguanide oral medication. Reduces liver glucose production and improves insulin sensitivity. First-line for type 2 diabetes since the UKPDS trial in 1998.
| Attribute | Semaglutide | Metformin |
|---|---|---|
| Generation | Gen 3 — synthetic peptide analog | Gen 1 — off-patent generic |
| FDA Approved | 2017 (Ozempic, T2D) 2021 (Wegovy, obesity) |
1995 (US), in use since 1957 globally |
| Cost (Uninsured) | $900–$1,300/month | $4–$15/month (generic) |
| Insurance Coverage | Partial — varies by plan and indication | Excellent — covered by all plans |
| A1c Reduction | 1.5–2.0% (SUSTAIN trials) | 1.0–1.5% (UKPDS, modern RCTs) |
| Weight Loss | 10–15% body weight (STEP trials) | Modest — 2–3% (neutral to slight loss) |
| Cardiovascular Benefit | Yes — proven (SUSTAIN-6, SELECT) | Yes — proven (UKPDS, modern meta-analyses) |
| Key Trials | SUSTAIN, STEP, SELECT (large RCTs) | UKPDS (1998), DPP (2002), dozens of modern RCTs |
| Side Effects | Nausea, vomiting, GI upset (common); pancreatitis warning | GI upset (common, usually temporary); rare lactic acidosis |
| Generic Available | No — patent cliff ~2033 | Yes — generic since 2002 |
If you've been to a peptide clinic or telehealth platform in the last 18 months, you've probably seen semaglutide marketed as a "revolutionary" weight loss solution. The pitch usually goes:
In the STEP-1 trial, participants received intensive behavioral therapy (diet counseling, exercise support) alongside semaglutide. Real-world results without that support structure are typically 5-7% weight loss, not 15%. The drug is a tool — the lifestyle change is the engine.
You have type 2 diabetes without significant cardiovascular disease or obesity, you're newly diagnosed, you don't have insurance coverage for semaglutide, or your A1c is < 8.0%. ADA guidelines still put metformin first.
You have T2D plus obesity (BMI ≥30) or cardiovascular disease, your A1c is still >7% on metformin, you can afford the $900/month or have insurance that covers it, and you're committed to lifestyle changes.
You have a personal or family history of medullary thyroid cancer or MEN-2 syndrome (black box warning), you have active pancreatitis, you're pregnant or planning pregnancy, or you can't afford it long-term.
Many endocrinologists now use metformin first, then add low-dose semaglutide for weight + cardiovascular benefit. The combination is more effective than either alone, and metformin is cheap.
A generic semaglutide would cost 80–95% less than the brand. Indian generic manufacturers (Cipla, Dr. Reddy's, Sun Pharma) already have bioequivalence data. The patent cliff is being aggressively defended by Novo Nordisk — they have 13+ patents listed in the Orange Book, with the last expiring in 2034. So a US generic is unlikely before 2034.
Semaglutide is a genuinely effective drug for type 2 diabetes with obesity, and for weight loss in people with obesity. It is also enormously expensive and aggressively marketed. Metformin is less effective for weight loss but excellent for A1c and cardiovascular outcomes, costs almost nothing, and has 70 years of safety data.
For most patients with type 2 diabetes, metformin should be tried first. Semaglutide should be added (or used instead) when there's a clear indication: obesity, cardiovascular disease, A1c not controlled on metformin alone, or patient preference after informed discussion of cost.
The peptide-clinic business model depends on patients skipping metformin and going straight to expensive semaglutide. The honest model starts with what's been proven over 70 years and adds what's newer only when the older one isn't enough.
Explore the complete pharmacological ladder for metabolic health — from berberine to tirzepatide. See costs, evidence, FDA status, and better starting points for every treatment.
Open the Navigator →